Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q14833
UPID:
GRM4_HUMAN
Alternative names:
-
Alternative UPACC:
Q14833; B3KVL9; B7Z1T9; B7Z1U6; F5GXM5; Q5SZ84; Q6ZMQ2
Background:
The Metabotropic Glutamate Receptor 4 (mGluR4) plays a pivotal role in neurotransmission, acting as a G-protein coupled receptor for glutamate. This receptor's activation leads to a conformational change, initiating signaling through G proteins and modulating the activity of downstream effectors, notably inhibiting adenylate cyclase.
Therapeutic significance:
Understanding the role of Metabotropic Glutamate Receptor 4 could open doors to potential therapeutic strategies. Its involvement in neurotransmission suggests its potential as a target in neurological disorders.